5-溴-3-氰基-2(1H)-吡啶酮 | 405224-22-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-溴-3-氰基-2(1H)-吡啶酮
• 中文别名: 5-溴-2-羟基烟腈；5-溴-3-氰基-2(1H)-吡啶酮,5-溴-3-氰基-2-羟基吡啶；5-溴-3-氰基-2-羟基吡啶；5-溴-2-羟基-3-氰基吡啶
• 英文名称: 5-bromo-2-oxo-1,2-dihydropyridine-3-carbonitrile
• 英文别名: 5-bromo-2-oxo-1H-pyridine-3-carbonitrile
• CAS: 405224-22-8
• 化学式: C₆H₃BrN₂O
• mdl: MFCD07363806
• 分子量: 199.007
• InChiKey: SWTLLSLCDHXNIU-UHFFFAOYSA-N

物化性质

• 熔点：
  219-221
• 沸点：
  292.1±40.0 °C(Predicted)
• 密度：
  1.84±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933399090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Bromo-3-cyano-2(1H)-pyridinone
Synonyms: 5-Bromo-2-hydroxy-3-pyridinecarbonitrile; 5-bromo-2-hydroxynicotinonitrile

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromo-3-cyano-2(1H)-pyridinone
CAS number: 405224-22-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H3BrN2O
Molecular weight: 199.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴-3-氰基-2(1H)-吡啶酮 在 hydrazine hydrate 、 五氯化磷 、 三氯氧磷 作用下， 以 乙醇 为溶剂， 生成 3-氨基-5-溴-1H-吡唑并[3,4-B]吡啶
  参考文献：
  名称：

  吡唑并吡啶异羟肟酸类化合物、其制备方法及其应用

  摘要：

  本发明涉及化学合成技术领域，具体而言，涉及吡唑并吡啶异羟肟酸类化合物、其制备方法及其应用。该吡唑并吡啶异羟肟酸类化合物包括式(1)所示化合物、其同分异构体、其水合物或其药学上可接受的盐，其中，n为整数，R为取代或未取代芳香环基团和取代烷基中的任意一种。其能够良好地抑制癌细胞增殖，继而对于肿瘤有优异的治疗效果。

  公开号：

  CN113321651B
• 作为产物：
  描述：

  2-氯-3-氰基吡啶 在 溴 、 溶剂黄146 作用下， 反应 11.5h， 生成 5-溴-3-氰基-2(1H)-吡啶酮
  参考文献：
  名称：

  基于片段的N-取代-5-（4-异丙基硫代苯酚）-2-羟基烟酰胺衍生物作为新型Mcl-1抑制剂的设计，合成和生物学评估

  摘要：

  我们先前已经报道了抗凋亡的Mcl-1蛋白，3-硫吗啡啉8-氧代8H-ac [1,2-b]吡咯9-腈（S1）的纳摩尔抑制剂。S1通过结合到Mcl-1的BH3凹槽发挥其功能。基于这种空间结构特征，我们使用基于片段的药物发现方法开发了一类新型的Mcl-1抑制剂。通过解剖S1，我们鉴定出具有2-羟基吡啶核的化合物4为起始片段。在随后的分子生长中，我们使用了配体效率评估和拟合质量得分来评估片段。新型有效化合物N-苄基-5-（4-异丙基硫代苯酚）-2-羟基烟酰胺（12c），获得结合Mcl-1的IC 50值为54 nM。化合物12c显示出比S1更好的水溶性。

  DOI：

  10.1016/j.ejmech.2012.12.016

文献信息

• [EN] PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF<br/>[FR] COMPOSÉS À BASE DE PYRIDINONE ET DE PYRIDAZINONE ET UTILISATIONS MÉDICALES ASSOCIÉES
  申请人：HLA TIMOTHY

  公开号：WO2019173790A1

  公开（公告）日：2019-09-12

  The various examples presented herein are directed to compounds of the formula A-L1-Het1-L2-Cy1 or a pharmaceutical acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein: A is cycloalkyl, aryl, arylalkyl or heterocyclyl; Het1 is heterocyclyl containing at least two heteroatoms; Cy1 is a heterocyclyl; L1 is a bond, alkyl, alkenyl or alkynyl linker; L2 is an acyl or alkyl linker; and A and Cy1 are different. The compounds are useful in the treatment of fibrotic diseases, abnormal vascular leak and pathological angiogenesis.

  本文提供的各种示例涉及到以下公式的化合物A-L1-Het1-L2-Cy1或其药用可接受的盐、多型体、前药、溶剂合物或包合物，其中：A为环烷基、芳基、芳基烷基或杂环烷基；Het1为含有至少两个杂原子的杂环烷基；Cy1为杂环烷基；L1为键、烷基、烯基或炔基连接物；L2为酰基或烷基连接物；A和Cy1不同。这些化合物在治疗纤维化疾病、异常血管渗漏和病理性血管生成方面具有用途。
• [EN] BIARYL KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES À BASE DE BIARYLE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017059085A1

  公开（公告）日：2017-04-06

  The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAKl (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.

  本公开涉及式(I)的双芳基化合物，该化合物能够抑制AAK1（适配器相关激酶1），包含此类化合物的组合物以及它们用于治疗例如疼痛、阿尔茨海默病、帕金森病和精神分裂症。
• [EN] BIARYL KINASE INHIBITORS<br/>[FR] INHIBITEURS BIARYLE DE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015153720A1

  公开（公告）日：2015-10-08

  The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

  本公开通常涉及能够抑制AAK1（适配器相关激酶1）的化合物、包含该化合物的组合物以及抑制AAK1的方法。
• ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS
  申请人：Pinto Donald J.P.

  公开号：US20100016316A1

  公开（公告）日：2010-01-21

  The present invention provides compounds of Formula (I) or (II): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L 1 , R 3 , R 4 , R 8a , R 11 and M are as defined herein. The compounds of Formula (I) or (II) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了化合物的结构式（I）或（II）： 或其立体异构体、互变异构体、药学上可接受的盐或溶剂形式，其中变量A、L1、R3、R4、R8a、R11和M如本文所定义。结构式（I）或（II）的化合物是凝血级联和/或接触激活系统的丝氨酸蛋白酶酶的选择性抑制剂；例如凝血酶、Xa因子、XIa因子、IXa因子、VIIa因子和/或血浆激肽。具体而言，涉及选择性XIa因子抑制剂或fXIa和血浆激肽的双重抑制剂的化合物。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。
• Design and synthesis of novel substituted naphthyridines as potential c-Met kinase inhibitors based on MK-2461
  作者：Jing-Fang Wu、Ming-Ming Liu、Shao-Xu Huang、Yang Wang

  DOI：10.1016/j.bmcl.2015.05.082

  日期：2015.8

  Two series of novel 1,5-naphthyridine and 1,6-naphthyridine derivatives were designed and synthesized based on the c-Met kinase inhibitor MK-2461 under the guidance of scaffold hopping strategy. All were tested on c-Met kinase and in vitro anti-tumor activities against Hela and A549 cell lines. The results indicated that 1,6-naphthyridine was a more promising c-Met inhibitory structure core compared

  在支架跳跃策略的指导下，基于c-Met激酶抑制剂MK-2461设计并合成了两个系列的新型1,5-萘啶和1,6-萘啶衍生物。所有测试均针对c-Met激酶以及针对Hela和A549细胞系的体外抗肿瘤活性。结果表明，与1，5-萘啶相比，1，6-萘啶是更有前途的c-Met抑制结构核心。其中，26b和26c表现出最好的酶和细胞毒性活性。Western blot实验表明26c的细胞毒活性可能部分是通过抑制c-Met激酶的磷酸化来实现的。